Immunogenicity and safety of cell-derived MF59®-adjuvanted A/H1N1 influenza vaccine for children

References

• Health Protection Agency. Pandemic (H1N1) 2009 in England: an overview of initial epidemiological findings and implications for the second wave (v4 2 December 2009). Available from: http://webarchive.nationalarchives.gov.uk/20140714084352/http://www.hpa.org.uk/web/HPAwebFile/HPAweb_C/1258560552857
   Google Scholar
• Miller E, Hoschler K, Hardelid P, Stanford E, Andrews N, Zambon M. Incidence of 2009 pandemic influenza A H1N1 infection in England: a cross-sectional serological study. Lancet 2010; 375:1100-8; PMID:20096450; http://dx.doi.org/10.1016/S0140-6736(09)62126-7
   PubMed Web of Science ®Google Scholar
• Sachedina N, Donaldson LJ. Paediatric mortality related to pandemic influenza A H1N1 infection in England: an observational population-based study. Lancet 2010; 376:1846-52; PMID:21030071; http://dx.doi.org/10.1016/S0140-6736(10)61195-6
   PubMed Web of Science ®Google Scholar
• World Health Organization. New influenza A (H1N1) virus: global epidemiological situation, June 2009. Wkly Epidemiol Rec 2009; 84:249-60; PMID:19537358
   PubMedGoogle Scholar
• Glezen WP, Couch RB. Interpandemic influenza in the Houston area, 1974-76. N Engl J Med 1978; 298:587-92; PMID:628375; http://dx.doi.org/10.1056/NEJM197803162981103
   PubMed Web of Science ®Google Scholar
• Basta NE, Chao DL, Halloran ME, Matrajt L, Longini IM, Jr. Strategies for pandemic and seasonal influenza vaccination of schoolchildren in the United States. Am J Epidemiol 2009; 170:679-86; PMID:19679750; http://dx.doi.org/10.1093/aje/kwp237
   PubMed Web of Science ®Google Scholar
• Medlock J, Galvani AP. Optimizing influenza vaccine distribution. Science 2009; 325:1705-8; PMID:19696313; http://dx.doi.org/10.1126/science.1175570
   PubMed Web of Science ®Google Scholar
• Yang Y, Sugimoto JD, Halloran ME, Basta NE, Chao DL, Matrajt L, Potter G, Kenah E, Longini IM Jr.. The transmissibility and control of pandemic influenza A (H1N1) virus. Science 2009; 326:729-33; PMID:19745114; http://dx.doi.org/10.1126/science.1177373
   PubMed Web of Science ®Google Scholar
• Jordan R, Connock M, Albon E, Fry-Smith A, Olowokure B, Hawker J, Burls A. Universal vaccination of children against influenza: are there indirect benefits to the community? A systematic review of the evidence. Vaccine 2006; 24:1047-62; PMID:16298026; http://dx.doi.org/10.1016/j.vaccine.2005.09.017
   PubMed Web of Science ®Google Scholar
• Clark TW, Pareek M, Hoschler K, Dillon H, Nicholson KG, Groth N, Stephenson I. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N Engl J Med 2009; 361:2424-35; PMID:19745215; http://dx.doi.org/10.1056/NEJMoa0907650
   PubMed Web of Science ®Google Scholar
• Alghisi F, Palma P, Montemitro E, Bernardi S, Pontrelli G, Rossi P, Lucidi V. Immunogenicity and safety profile of the monovalent A/H1N1 MF59-adjuvanted vaccine in patients affected by cystic fibrosis. Thorax 2011; 66:259-60; PMID:21228426; http://dx.doi.org/10.1136/thx.2010.156018
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Haertel S, Praus M. Passive surveillance of adverse events of an MF59-adjuvanted H1N1v vaccine during the pandemic mass vaccinations. Hum Vaccin 2011; 7:539-48; PMID:21422814; http://dx.doi.org/10.4161/hv.7.5.14821
   PubMed Web of Science ®Google Scholar
• Esposito S, D'Angelo E, Daleno C, Peia F, Scala A, Serra D, Mirra N, Galeone C, Principi N. Immunogenicity, safety and tolerability of monovalent 2009 pandemic influenza A/H1N1 MF59-adjuvanted vaccine in patients with beta-thalassemia major. Vaccine 2010; 28:7825-8; PMID:20888873; http://dx.doi.org/10.1016/j.vaccine.2010.09.058
   PubMedGoogle Scholar
• Esposito S, Meregalli E, Daleno C, Peia F, Scala A, Serra D, Mirra N, Galeone C, Principi N. An open-label, randomized clinical trial assessing immunogenicity, safety and tolerability of pandemic influenza A/H1N1 MF59-adjuvanted vaccine administered sequentially or simultaneously with seasonal virosomal-adjuvanted influenza vaccine to paediatric kidney transplant recipients. Nephrol Dial Transplant 2011; 26:2018-24; PMID:20974645; http://dx.doi.org/10.1093/ndt/gfq657
   PubMed Web of Science ®Google Scholar
• Esposito S, Tagliaferri L, Daleno C, Valzano A, Picciolli I, Tel F, Prunotto G, Serra D, Galeone C, Plebani A, et al. Pandemic influenza A/H1N1 vaccine administered sequentially or simultaneously with seasonal influenza vaccine to HIV-infected children and adolescents. Vaccine 2011; 29:1677-82; PMID:21199699; http://dx.doi.org/10.1016/j.vaccine.2010.12.047
   PubMed Web of Science ®Google Scholar
• Kajaste-Rudnitski A, Galli L, Nozza S, Tambussi G, Di Pietro A, Pellicciotta G, Monti A, Mascagni P, Moro M, Vicenzi E. Induction of protective antibody response by MF59-adjuvanted 2009 pandemic A/H1N1v influenza vaccine in HIV-1-infected individuals. AIDS 2011; 25:177-83; PMID:21150561; http://dx.doi.org/10.1097/QAD.0b013e328341afa8
   PubMed Web of Science ®Google Scholar
• Pellegrini M, Nicolay U, Lindert K, Groth N, Della Cioppa G. MF59-adjuvanted versus non-adjuvanted influenza vaccines: integrated analysis from a large safety database. Vaccine 2009; 27:6959-65; PMID:19751689; http://dx.doi.org/10.1016/j.vaccine.2009.08.101
   PubMed Web of Science ®Google Scholar
• Schultze V, D'Agosto V, Wack A, Novicki D, Zorn J, Hennig R. Safety of MF59 adjuvant. Vaccine 2008; 26:3209-22; PMID:18462843; http://dx.doi.org/10.1016/j.vaccine.2008.03.093
   PubMed Web of Science ®Google Scholar
• Tsai TF, Crucitti A, Nacci P, Nicolay U, Della Cioppa G, Ferguson J, Clemens R. Explorations of clinical trials and pharmacovigilance databases of MF59((R))-adjuvanted influenza vaccines for associated cases of narcolepsy. Scand J Infect Dis 2011; 43:702-6; PMID:21534891
   PubMed Web of Science ®Google Scholar
• Banzhoff A, Pellegrini M, Del Giudice G, Fragapane E, Groth N, Podda A. MF59-adjuvanted vaccines for seasonal and pandemic influenza prophylaxis. Influenza Other Respir Viruses 2008; 2:243-9; PMID:19453401; http://dx.doi.org/10.1111/j.1750-2659.2008.00059.x
   PubMed Web of Science ®Google Scholar
• Durando P, Icardi G, Ansaldi F. MF59-adjuvanted vaccine: a safe and useful tool to enhance and broaden protection against seasonal influenza viruses in subjects at risk. Expert Opin Biol Ther 2010; 10:639-51; PMID:20218923; http://dx.doi.org/10.1517/14712591003724662
   PubMed Web of Science ®Google Scholar
• El Sahly H. MF59™ as a vaccine adjuvant: a review of safety and immunogenicity. Expert Rev Vaccines 2010; 9:1135-41; PMID:20923265; http://dx.doi.org/10.1586/erv.10.111
   PubMed Web of Science ®Google Scholar
• O'Hagan DT. MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection. Expert Rev Vaccines 2007; 6:699-710; PMID:17931151; http://dx.doi.org/10.1586/14760584.6.5.699
   PubMed Web of Science ®Google Scholar
• Tsai T, Kyaw MH, Novicki D, Nacci P, Rai S, Clemens R. Exposure to MF59-adjuvanted influenza vaccines during pregnancy–a retrospective analysis. Vaccine 2010; 28:1877-80; PMID:19969117; http://dx.doi.org/10.1016/j.vaccine.2009.11.077
   PubMed Web of Science ®Google Scholar
• Global alert and response: WHO recommendations on pandemic (H1N1) 2009 vaccines. Geneva. World Health Organization, 2009. Available from: http://www.who.int/csr/disease/swineflu/notes/h1n1_vaccine_20090713/en/index.html
   Google Scholar
• Plennevaux E, Sheldon E, Blatter M, Reeves-Hoche MK, Denis M. Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. Lancet 2010; 375:41-8; PMID:20018365; http://dx.doi.org/10.1016/S0140-6736(09)62026-2
   PubMed Web of Science ®Google Scholar
• Oh CE, Lee J, Kang JH, Hong YJ, Kim YK, Cheong HJ, Ahn YJ, Kim SH, Lee HJ. Safety and immunogenicity of an inactivated split-virus influenza A/H1N1 vaccine in healthy children from 6 months to. Vaccine 2010; 28:5857-63; PMID:20600483; http://dx.doi.org/10.1016/j.vaccine.2010.06.060
   PubMed Web of Science ®Google Scholar
• Black S, Nicolay U, Vesikari T, Knuf M, Del Giudice G, Della Cioppa G, Tsai T, Clemens R, Rappuoli R. Hemagglutination inhibition antibody titers as a correlate of protection for inactivated influenza vaccines in children. Pediatr Infect Dis J 2011; 30:1081-5; PMID:21983214; http://dx.doi.org/10.1097/INF.0b013e3182367662
   PubMed Web of Science ®Google Scholar
• Beyer WE, Nauta JJ, Palache AM, Giezeman KM, Osterhaus AD. Immunogenicity and safety of inactivated influenza vaccines in primed populations: a systematic literature review and meta-analysis. Vaccine 2011; 29:5785-92; PMID:21624411; http://dx.doi.org/10.1016/j.vaccine.2011.05.040
   PubMed Web of Science ®Google Scholar
• Vesikari T, Pellegrini M, Karvonen A, Groth N, Borkowski A, O'Hagan DT, Podda A. Enhanced immunogenicity of seasonal influenza vaccines in young children using MF59 adjuvant. Pediatr Infect Dis J 2009; 28:563-71; PMID:19561422; http://dx.doi.org/10.1097/INF.0b013e31819d6394
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. CPMP/BWP/214/96 Note for guidance on harmonization of requirements for influenza vaccines. Available from: http://www.ema.europa.eu/ema/pages/includes/document/open_document.jsp?webContentId=WC500003945
   Google Scholar